Verinata

Redwood City, United States Founded: 2002 • Age: 24 yrs Acquired By Illumina
Non-invasive prenatal tests for fetal chromosomal abnormalities are developed.
Annual revenue - Latest available
Total funding $58.2M 3 rounds
Employees 2 Tracked headcount
Investors 4 Known backers
Products - Services tracked
Competitors 11 Brand Intelligence

About Verinata

Verinata is a company based in Redwood City (United States) founded in 2002 was acquired by Illumina in January 2013. Verinata has raised $58.25 million across 3 funding rounds from investors including Illumina, Mohr Davidow Ventures and Sutter Hill Ventures. The company has 2 employees as of February 28, 2019. Verinata operates in a competitive market with competitors including Natera, BillionToOne, Progenity, SYNLAB and Beikang Medical, among others.

  • Headquarter Redwood City, United States
  • Employees 2 as on 28 Feb, 2019
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Verinata Health, Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Health Technology & Digital Health Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $58.25 M (USD)

    in 3 rounds

  • Latest Funding Round
    $750 K (USD), Series C

    May 09, 2012

  • Investors
    Illumina

    & 3 more

  • Employee Count
    2

    as on Feb 28, 2019

  • Acquired by
    Illumina

    (Jan 07, 2013)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Verinata

Verinata has successfully raised a total of $58.25M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $750 thousand completed in May 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Verinata

Verinata has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Illumina, Mohr Davidow Ventures and Sutter Hill Ventures.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital investments are managed in technology and healthcare sectors by this firm.
Locked Locked Locked
VC firm investing in the US
Locked Locked Locked
Early stage venture capital firm investing in the US
Locked Locked Locked
Premium access

Investor details for Verinata

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Verinata

Investments
Premium access

Investment portfolio details for Verinata

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Verinata

Premium access

Detailed financials for Verinata

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Verinata Comparisons

Verinata Primary company
Description
Non-invasive prenatal tests for fetal chromosomal abnormalit...
Location
Redwood City, United States
Founded Year
2002
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
2
As of 2019
Premium access

Peer comparison for Verinata

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Verinata

Verinata operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Natera, BillionToOne, Progenity, SYNLAB and Beikang Medical, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Developer of cell-free DNA testing for oncology, women’s health, and organ health
Locked Locked Locked
Provider of cell-free cancer liquid biopsy test
Locked Locked Locked
Non-invasive prenatal genomic testing is provided for genetic disorders.
Locked Locked Locked
Provider of medical diagnosis and clinical laboratory analysis services
Locked Locked Locked
NGS-based diagnostic solutions for neonatal screening are developed.
Locked Locked Locked
Non-invasive prenatal genetic tests and genomic services are provided.
Premium access

Detailed competitors of Verinata

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Verinata

Premium access

Complete news archive for Verinata

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Verinata

Verinata was founded in 2002 and raised its 1st funding round 7 years after it was founded.

Verinata is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.

Verinata is a funded company, having raised a total of $58.25M across 3 funding rounds to date.

As of Feb 28, 2019, the latest employee count at Verinata is 2.

Verinata Health, formerly known as Artemis Health developed prenatal genetic tests that helped detect fetal chromosomal abnormalities by analyzing a small amount of the mothers blood. Its test, Verifi, tested cell free fetal DNA in the mothers bloodstream for aneuploidies like Down syndrome (trisomy 21 or T21), Edwards syndrome (trisomy 18 or T18) and Patau syndrome (trisomy 13 or T13). In addition, the test also detects sex chromosome aneuploidies like Turner syndrome (Monosomy X), Triple X (XXX), Klinefelter syndrome (XXY) and Jacobs syndrome (XYY). In January 2013, Illumina acquired Verinata for 350 million upfront, with an additional 100 million in milestone payments.

Verinata's top competitors include Natera, BillionToOne and Pictor.

Verinata has 4 investors. Key investors include Illumina, Mohr Davidow Ventures, Sutter Hill Ventures, and Alloy Ventures.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available